1. A Closer Look

2. Goals of Preventive Treatment for Migraine

3. Migraine Is Inadequately Treated

4. Features of Optimal Preventive Treatments

5. Pathophysiology of Migraine

6. A Role for CGRP-Targeting Therapy in Migraine

7. Early Trials of CGRP-Targeting Small Molecules for the Treatment of Migraine

8. CGRP-Targeting mAbs for Migraine Prevention

9. Clinical Benefit of Anti-CGRP mAbs 50% Responder Rate in EM

10. Clinical Benefit of Anti-CGRP mAbs 75% Responder Rate in EM

11. Onset of Efficacy and AEs of Migraine Preventive Therapies

12. FDA-Approved Anti-CGRP mAbs Prevention of EM and CM

13. Unanswered Questions

14. Erenumab in Patients With Cardiovascular Disease

15. Using Anti-CGRP mAbs in Clinical Practice Real-World Example

16. Incorporating Anti-CGRP mAbs Into the Treatment Paradigm

17. Which Patients Might Benefit?

18. Which Patients Should Proceed With Caution?

19. Conclusions

20. Abbreviations

21. Abbreviations (cont)